COMPASS Pathways plc

CMPS

US20451W1018

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
7.94 ^USD	+1.02%		-5.25%	-9.26%

Apr. 18	Compass Pathways Insider Sold Shares Worth $597,964, According to a Recent SEC Filing	MT
Apr. 18	Compass Pathways Insider Sold Shares Worth $597,964, According to a Recent SEC Filing	MT

COMPASS Pathways plc(NasdaqGS:CMPS) dropped from NASDAQ Biotechnology Index

December 15, 2023 at 12:00 am EST

COMPASS Pathways plc has been removed from NASDAQ Biotechnology Index.

Latest news about COMPASS Pathways plc

Compass Pathways Insider Sold Shares Worth $597,964, According to a Recent SEC Filing	Apr. 18	MT
Compass Pathways Insider Sold Shares Worth $597,964, According to a Recent SEC Filing	Apr. 18	MT
Clarify Pharma to change name to File Forge Technology	Apr. 17	AN
Compass Pathways Insider Sold Shares Worth $461,332, According to a Recent SEC Filing	Apr. 02	MT
Compass Pathways Insider Sold Shares Worth $461,332, According to a Recent SEC Filing	Apr. 02	MT
Compass Pathways Insider Sold Shares Worth $445,552, According to a Recent SEC Filing	Apr. 01	MT
Compass Pathways Insider Sold Shares Worth $445,552, According to a Recent SEC Filing	Apr. 01	MT
Morgan Stanley Initiates COMPASS Pathways at Overweight With $30 Price Target	Apr. 01	MT
ADRs End Lower; NuCana Slides 15%	Mar. 28	DJ
Compass Pathways Co-Founders Step Down From Board; David Norton Named Interim Chair; Shares Fall	Mar. 28	MT
COMPASS Pathways plc Announces Board Changes	Mar. 28	CI
Compass Pathways Insider Sold Shares Worth $704,821, According to a Recent SEC Filing	Mar. 15	MT
Compass Pathways Insider Sold Shares Worth $704,821, According to a Recent SEC Filing	Mar. 15	MT
Transcript : COMPASS Pathways plc, Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
COMPASS Pathways plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
COMPASS Pathways plc Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Compass Pathways Insider Sold Shares Worth $609,862, According to a Recent SEC Filing	Feb. 27	MT
Compass Pathways Insider Sold Shares Worth $609,862, According to a Recent SEC Filing	Feb. 27	MT
Compass Pathways Insider Sold Shares Worth $902,124, According to a Recent SEC Filing	Feb. 08	MT
Compass Pathways Insider Sold Shares Worth $902,124, According to a Recent SEC Filing	Feb. 08	MT
Compass Pathways Insider Sold Shares Worth $752,954, According to a Recent SEC Filing	Jan. 23	MT
Compass Pathways Insider Sold Shares Worth $752,954, According to a Recent SEC Filing	Jan. 23	MT
Compass Pathways plc Enters into Research Collaboration Agreement with Hackensack Meridian Health to Develop Optimal Clinical Model for Investigational Comp360 Psilocybin Treatment, If FDA-Approved	Jan. 16	CI
ADRs Slump, Grifols S.A. Declines 14.0%	Jan. 11	DJ
Compass Pathways, Greenbrook TMS Start Research Collaboration on Psilocybin Treatment	Jan. 05	MT

Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in the development of psilocybin treatment, in which its investigational COMP360 psilocybin is administered in conjunction with psychological support, COMP360 psilocybin treatment. COMP360 is its proprietary psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Companyâs initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.94 USD

Average target price

41.25 USD

Spread / Average Target

+419.52%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
COMPASS PATHWAYS PLC	-9.26%	543M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+48.32%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research